The Wire China · China
TIER 4 Mon, 15 Dec 2025 00:14:56 +0000
|
Illustration by Sam Ward
| China’s Search for an AI Magic Cure Dr Mao Hongjing is a highly sought-after expert on depression and sleeping disorders who sees about 20 patients a day in Hangzhou, one of China’s most modern and attractive cities. Now meet his avatar which can advise 30,000 patients a day, according to the company whose healthcare AI app created it. And as Rachel Cheung writes in this week’s cover, those tens of thousands of patients need not come to Hangzhou, but can access his expertise from some of the country’s most medically under-served regions. Such is the promise of healthcare AI in China. But is the promise real and, even if it is, who will pay for it?
U.S. Vice President JD Vance delivers a keynote address at The Bitcoin Conference in Las Vegas, Nevada, May 28, 2025. Credit: Ethan Miller via Getty Images
| Friends or Foes? China banned crypto currency mining in 2021 but, as Noah Berman writes, that hasn’t prevented Chinese companies from dominating the markets for crypto mining and related computers. Many of them are also active in the U.S. In Washington, China hawks are starting to look askance at these corporate refugees fleeing a hostile homeland, worrying that they pose a threat to American national security interests. On the other side of the argument, U.S. crypto miners worry about becoming collateral damage if the Trump administration “panics [its] way into a policy that needlessly damages American miners, American energy projects and American jobs based on unproven allegations”.
Credit:Adobe Stock
| China’s Biggest Pharmaceutical Company and the Power Couple Behind It The subject of this week’s Big Picture Company in the News profile is state-owned Jiangsu Hengrui Medicine Company, aka Hengrui Pharma. It is China’s biggest pharmaceutical company and earlier this year secured a $500 million deal, which could eventually be worth as much as $12 billion, with GSK of the UK. Chairman Sun Piaoyang and his wife Zhong Huijian, who controls a rival drug company, have a combined net worth of more than $36 billion, according to Forbes.
Few people have done more than Jin Liqun to promote Chinese soft power. When the outgoing head of the China-led Asian Infrastructure Investment Bank was named to lead the fledgling institution a decade ago, the Obama administration tried to dissuade U.S. allies from joining it. They did so anyway and under Jin’s stewardship the AIIB has established itself as a credible and respected multinational lender with an internationally diverse staff. In a valedictory conversation with Andrew Peaple, Jin talks about the AIIB’s relationship with the Chinese Communist Party, lending to more projects beyond Asia and the bank’s decision to freeze lending to projects in Russia and Belarus after Vladimir Putin’s invasion of Ukraine. Jin Liqun
Illustration by Lauren Crow
A clerk counts RMB banknotes prepared for depositors at a bank in Nantong, Jiangsu, China. Credit: IC Photo via Depositphotos
| How China is Weakening the Renminbi China is quietly using its state banks to weaken the renminbi, Brad Setser writes in this week’s op-ed. This has helped the country’s goods trade surplus to soar past $1 trillion this year despite the imposition of U.S. tariffs. It’s high time, he argues, for the Trump administration to act.
| Subscribe today for unlimited access.
Starting at only $25 a month.
| Want to change how you receive these emails?
You can unsubscribe from this list.
The Wire
New York, NY
| This email was sent to stephen.shu.zhang@gmail.com
why did I get this? unsubscribe from this list update subscription preferences
The Wire China * The Wire * New York, New York 10122 * USA